Profound Medical Reports Strong Revenue Growth, Key Clinical Milestones, and Successful Capital Raise in Annual Report

summarizeSummary

Profound Medical's annual report reveals strong revenue growth, significant clinical trial completion, and a new CPT code for its TULSA-PRO system, supported by a recent capital raise, despite increased net losses.

check_boxKey Events

• Strong Revenue Growth and Improved Gross Margin

  The company reported a 51% increase in revenue to $16.098 million for the year ended December 31, 2025, up from $10.680 million in 2024. Gross profit grew by 62% to $11.393 million, with the gross margin improving from 66% to 71%.

• Significant Capital Raise Completed

  In December 2025, Profound Medical successfully closed a public offering and a private placement, issuing a total of 6,064,298 common shares at $7.00 per share, generating gross proceeds of $42.45 million. This financing provides crucial liquidity for operations over the next 12-18 months.

• Pivotal CAPTAIN Clinical Trial Completed with Positive Outcomes

  Enrollment and treatment for the CAPTAIN trial, comparing the TULSA procedure to robotic radical prostatectomy, were completed in 2025. Perioperative outcomes presented in 2025 demonstrated TULSA's superiority in blood loss, length of stay, post-procedure pain, and recovery to baseline activities.

• New Category 1 CPT Code for TULSA Procedure

  A Category 1 CPT code for the TULSA procedure became effective on January 1, 2025, with Medicare National Average payment rates of $13,479 for Hospital Outpatient (HOPD) and $10,874 for Ambulatory Surgical Centers (ASC). This is a significant step for reimbursement and market adoption.

auto_awesomeAnalysis

Profound Medical's annual report highlights significant progress in its commercialization strategy and clinical development. The 51% revenue growth and improved gross margin demonstrate increasing market adoption for its TULSA-PRO system. The completion of the pivotal CAPTAIN trial with positive perioperative outcomes and the establishment of a Category 1 CPT code for the TULSA procedure are critical milestones that de-risk future commercialization and reimbursement. While the company continues to incur substantial losses and relies on external financing, the successful $42.45 million capital raise in December 2025 provides essential liquidity for the next 12-18 months. The remediation of a material weakness in internal controls also signals improved corporate governance. Investors should monitor continued market penetration and progress towards profitability.